SCH 52365 Phase II Clinical Study: A Study on the Efficacy and Safety of Monotherapy With SCH 52365 in Patients With First Relapsed Anaplastic Astrocytoma (Study P03745)

This study has been completed.
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp. Identifier:
First received: October 30, 2008
Last updated: April 8, 2015
Last verified: April 2015
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: June 2005
  Primary Completion Date: June 2005 (Final data collection date for primary outcome measure)